Pearl Steinzor

Aficamten improved exercise capacity across submaximal, peak, and recovery measures.

Elena Koundourakis, PhD, discusses phase 3 trial improvements in cognition, REM normalization, and nighttime sleep quality in patients with narcolepsy.

David Brueggeman, MBA, breaks down the underpriced financial risks, redetermination lessons, and what accountable AI actually requires from health plans.

Adam Spira, PhD, MA, discusses how composite measures of sleep health may offer a modifiable target to reduce dementia risk.

Richard Bogan, MD, discusses trial data coming out of the VIBRANCE studies for patients with narcolepsy type 2 and idiopathic hypersomnia.

An 18-month Illinois pilot linking prison clinicians to endocrinologists via telehealth achieved a mean HbA1c reduction of 1.6 percentage points across 115 incarcerated men with diabetes.

Nathanael Hwang discusses how EHR-based machine learning models are adding value to patients with obstructive sleep apnea.

Salma Patel, MD, shares findings from the implementation of combination therapy recommendations for patients with chronic insomnia.

A pooled nonrandomized trial of AAVrh.10hFXN across 17 patients showed reduced LVMI and lower high-sensitivity troponin I levels at all 3 dose cohorts.

Sunil Sharma, MD, discusses the consequences of not diagnosing patients with sleep-disordered breathing during hospital admission.

Mark Malesker, PharmD, discusses the clinical evidence, drug interaction risks, and formulary challenges surrounding cannabinoid use for sleep disorders.

Sandra Chaparro, MD, discusses using obesity medications in patients with heart failure.

Shields Health Solutions is collaborating with Baptist Health to launch an integrated onsite specialty pharmacy at Baptist MD Anderson Cancer Center.

The FDA approved a supplemental BLA for Organon's tocilizumab biosimilar Tofidence.

MS was not linked to worse cardiovascular surgery outcomes, though routine home discharge was lower in this population.

Sandra Chaparro, MD, makes the case for SGLT2 inhibitors across a broad spectrum of chronic kidney disease, even in patients without diabetes.

Orforglipron added to titrated insulin glargine reduced HbA1c at 40 weeks while producing clinically meaningful weight reductions.

Late-breaker data from EASL Congress 2026 mark a pivotal moment in chronic hepatitis B research.

Surgical therapy for diabetic gastroparesis was associated with meaningful reductions in HbA1c and lower rates of diabetes-related complications.

Acoramidis treatment sustained reductions in all-cause mortality, cardiovascular mortality, and first cardiovascular hospitalization through 54 months.

A post hoc analysis found that worsening symptoms, declining quality of life, and rising NT-proBNP levels frequently precede sudden death in HFmrEF/HFpEF.

Heat-attributable CVD burden could reach 418 DALYs per 100,000 by 2050 under high-emissions scenarios, with low-income counties hit hardest.

New data showed durable hepatitis D virus RNA suppression through 96 weeks with tobevibart plus elebsiran, while higher BMI appeared to affect ALT normalization.

Two posters presented at EASL 2026 clarify where peginterferon alfa-2b fits in therapy for patients with chronic hepatitis B.

Heiner Wedemeyer, MD, offered an unflinching assessment of viral hepatitis medicine, celebrating landmark breakthroughs while issuing a clear warning that the field is failing the populations it set out to protect.

The approval is based on results from MannKind's phase 3 INHALE-1 clinical trial.

New data highlight pevifoscorvir’s potent antiviral activity and sustained hepatitis B antigen suppression lasting up to 96 weeks after treatment.

Full results from the pivotal B-Well 1 and B-Well 2 phase 3 trials confirm that bepirovirsen delivers statistically significant functional cure rates in chronic hepatitis B.

Two posters presented at the EASL Congress 2026 highlight promising clinical and preclinical findings for AHB-137.

A turbulent regulatory environment is forcing covered entities to rethink how they manage 340B compliance.